Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives

被引:124
作者
Sriram, D [1 ]
Yogeeswari, P
Basha, JS
Radha, DR
Nagaraja, V
机构
[1] Birla Inst Technol & Sci, Pharm Grp, Med Chem Res Lab, Pilani 333031, Rajasthan, India
[2] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India
关键词
antimycobacterial; anti-TB; ciprofloxacin derivatives; DNA gyrase inhibition;
D O I
10.1016/j.bmc.2005.05.063
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tuberculosis continues to be a major cause of morbidity and mortality all over the world. Various 7-substituted ciprofloxacin derivatives were synthesized and evaluated for antimycobacterial activity in vitro and in vivo against Mycobacterium tuberculosis and for inhibition of the supercoiling activity of DNA gyrase from Mycobacterium smegmatis. Preliminary results indicated that most of the compounds demonstrated better in vitro antimycobacterial activity against M. tuberculosis than ciprofloxacin. Compound 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[[N-4-[1'-(5- methylisatinyl-ss-semicarbazo)]methyl]N'-piperazinyl]-3-quinoline carboxylic acid (3h) decreased the bacterial load in spleen tissue with 0.76-log(10) protections and was considered to be moderately active in reducing bacterial count in spleen. The results demonstrated the potential and importance of developing new quinolone derivatives against mycobacterial infections. (c) 2005 Published by Elsevier Ltd.
引用
收藏
页码:5774 / 5778
页数:5
相关论文
共 17 条
[1]   The clinical use of fluoroquinolones for the treatment of mycobacterial diseases [J].
Alangaden, GJ ;
Lerner, SA .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) :1213-1221
[2]   TRANSMISSION OF TUBERCULOSIS IN NEW-YORK-CITY - AN ANALYSIS BY DNA-FINGERPRINTING AND CONVENTIONAL EPIDEMIOLOGIC METHODS [J].
ALLAND, D ;
KALKUT, GE ;
MOSS, AR ;
MCADAM, RA ;
HAHN, JA ;
BOSWORTH, W ;
DRUCKER, E ;
BLOOM, BR .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (24) :1710-1716
[3]  
Besra Gurdyal S., 1994, P285
[4]   Effect of different classes of inhibitors on DNA gyrase from Mycobacterium smegmatis [J].
Chatterji, M ;
Unniraman, S ;
Mahadevan, S ;
Nagaraja, V .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :479-485
[5]   Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium [J].
Collins, LA ;
Franzblau, SG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1004-1009
[6]   Progress in TB drug development and what is still needed [J].
Duncan, K .
TUBERCULOSIS, 2003, 83 (1-3) :201-207
[7]   Fluoroquinolones, tuberculosis, and resistance [J].
Ginsburg, AS ;
Grosset, JH ;
Bishai, WR .
LANCET INFECTIOUS DISEASES, 2003, 3 (07) :432-442
[8]   Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice [J].
Lenaerts, AJM ;
Gruppo, V ;
Brooks, JV ;
Orme, IM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :783-785
[9]   Recent Progress Towards the Identification of Inhibitors of Mycobacterial Cell Wall Polysaccharide Biosynthesis [J].
Lowary, Todd L. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2003, 3 (07) :689-702
[10]   Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase [J].
Manjunatha, UH ;
Dalal, M ;
Chatterji, M ;
Radha, DR ;
Visweswariah, SS ;
Nagaraja, V .
NUCLEIC ACIDS RESEARCH, 2002, 30 (10) :2144-2153